Pharmacological research

Blocking Topoisomerase I May Act as a Tumor Vaccine by Triggering a Viral RNA and Immune Response Pathway

Updated

Abstract

Irinotecan (CPT-11) triggered dsRNA accumulation in cancer models, activating immune responses.

  • Topoisomerase I (TOP1) may induce endogenous dsRNA through suppression of endogenous retroviruses.
  • Pharmacological inhibition of TOP1 using CPT-11 is associated with activation of the RIG-I/MDA5-MAVS pathway and antiviral responses.
  • CPT-11 treatment remodels the tumor microenvironment, promoting the infiltration of immune cells such as dendritic cells, macrophages, and T cells.
  • Combining CPT-11 with PD-1 blockade in 'cold' tumors could improve survival outcomes.
  • CPT-11 may generate a strong in situ vaccine effect, establishing immunological memory that prevents subsequent tumor growth.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free